Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00034840 · ClinicalTrials.gov registry record · Phase 4

Telmisartan vs. Valsartan in Patients With Mild to Moderate Hypertension Following a Missed Dose

A Phase 4 study of Hypertension, sponsored by Boehringer Ingelheim.

Completed
Registry status
Phase 4
Development phase
490
Enrollment target
20
Study locations

NCT00034840 is a Phase 4 study of Hypertension that has completed, run by Boehringer Ingelheim. The registered enrollment target is 490 participants, below the 3,506-participant average among 470 other Hypertension trials with a reported enrollment target (86% lower). The trial reports 20 study locations across 15 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00034840, a Phase 4 study of Hypertension, has completed, sponsored by Boehringer Ingelheim.

COMPLETED
Registry status
Phase 4
Development phase
490 participants
Enrollment target
20
Study locations

Study Summary

The primary objectives are to demonstrate that MICARDIS® (telmisartan) is statistically superior to Diovan® (valsartan) in reducing diastolic blood pressure (DBP) following a missed dose at the end of a 6 to 8-week treatment period as measured by the 24-hour ABPM mean and to demonstrate that MICARDIS® is statistically superior to Diovan® in reducing DBP during the last 6-hours of the 24-hour dosing interval as measured by ABPM following a dose of active study medication at the end of a 6 to 8-week treatment period.

Conditions Studied

Hypertension

Interventions

  • DRUG telmisartan, valsartan

Study Locations (20)

California

  • Memorial Research Medical Clinic - Long Beach
  • National Research Institute - Los Angeles
  • Orange County Research Center - Orange

Florida

  • Alan Graff - Fort Lauderdale
  • Greater Ft. Lauderdale Heart Group Research - Fort Lauderdale
  • Orlando Clinical Research Center - Orlando

Nova Scotia

  • Dr. William Booth - Antigonish Nova Scotia
  • MSHJ Research Assoc. - Halifax

Connecticut

  • University of Conn. Health Services Center, Hypertension and Vascular Disease - Farmington

Georgia

  • So. Clinical Research and Management, Inc. - Augusta

Illinois

  • Rush Presbyterian/St. Luke's Medical Center - Chicago

Maryland

  • University of Maryland/Nephrology Clinical Research Unit - Baltimore

Missouri

  • Washington University - St Louis

Trial Details

FieldValue
Enrollment Target 490 participants
Start Date 2001-10
Est. Completion 2002-08
Phase Phase 4

Sponsor

Boehringer Ingelheim

515 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00034840

The ClinicalTrials.gov registry entry for NCT00034840 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 490 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 3,506-participant average among 470 other Hypertension trials with a reported enrollment target (86% lower). The listed sponsor is Boehringer Ingelheim, which has 515 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Hypertension appearing as the primary indexed condition, and to 1 intervention - of which telmisartan, valsartan is the first listed.

NCT00034840 reports 20 study locations spanning 15 distinct geographic areas - top geographies include California, Florida, Nova Scotia.

Frequently Asked Questions

What is clinical trial NCT00034840 about?

NCT00034840 is a clinical study titled "Telmisartan vs. Valsartan in Patients With Mild to Moderate Hypertension Following a Missed Dose". The primary objectives are to demonstrate that MICARDIS® (telmisartan) is statistically superior to Diovan® (valsartan) in reducing diastolic blood pressure (DBP) following a missed dose at the end of a 6 to 8-week treatment period as measured by the 24-hour ABPM mean and to demonstrate that MICARDI...

What is the current status of trial NCT00034840?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 490 participants. The study started on 2001-10. Estimated completion is 2002-08.

What conditions does trial NCT00034840 study?

This clinical trial studies the following conditions: Hypertension.

What interventions are being tested in trial NCT00034840?

The interventions under investigation include: telmisartan, valsartan (DRUG).

Who is sponsoring clinical trial NCT00034840?

This trial is sponsored by Boehringer Ingelheim, which has 515 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00034840 being conducted?

This trial has 20 study locations across California, Connecticut, Florida, Georgia, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Hypertension

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Hypertension

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.